N-methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT(1D) receptor agonist

Journal of Medicinal Chemistry

Volumn 42, Issue 3, 1999, Pages 526-531

  Xu, Yao Chang ^a   Schaus, John M ^a   Walker, Clint ^a   Krushinski, Joe ^a   Adham, Nika ^b   Zgombick, John M ^b   Liang, Sidney X ^a   Kohlman, Dan T ^a   Audia, James E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; FROVATRIPTAN; N METHYL 5 TERT BUTYLTRYPTAMINE; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MIGRAINE; NEUROPHARMACOLOGY; SEROTONINERGIC SYSTEM; STRUCTURE ACTIVITY RELATION;

CELL LINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 0033048502     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9805945     Document Type: Article

References (41)

1. (a) Fuller, R. W. Adv. Drug Res. 1988, 17, 349-380.
2. (b) Glennon, R. A. Serotonin Receptors: Clinical Implications. Neurosci. Behav. Rev. 1990, 14, 35-47.
3. (a) Bradley, P. B.; Engle, G.; Feniuk, W.; Fozard, J. R.; Humphrey, P. P. A.; Middlemiss, D. N.; Mylecharane, E. J.; Richardson, B. P.; Saxena, P. R. Neuropharmacology 1986, 25, 563-576.
4. (b) Peroutka, S. J. Trends Neurosci. 1988, 11, 496-500.
5. (c) Hibert, M. F.; Mir, A. K.; Fozard, J. R. In Comprehensive Medicinal Chemistry; Hansch, C.; Sammes, P., Taylor, J., Eds.; Pergamon Press: Oxford, 1990; Vol. 3, Chapter 12.9, p 567.
6. (d) Weinshank, R. L.; Zgombick, J. M.; Macchi, M.; Branchek, T. A.; Hartig, P. R. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3630-3634.
7. (e) Levy, F. O.; Gudermann, T.; Birnbaymer, M.; Kaumann, A. J.; Birnbaumer, L. FEBS Lett. 1992, 296, 201-206.
8. (f) Adham, N.; Kao, H. T.; Schechter, L. E.; Bard, J.; Olsen, M.; Urquhart, D.; Durkin, M.; Hartig, P. R.; Weinshank, R. L. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 408-412.
9. (a) Ferrari, M. D. Sumatriptan in the Treatment of Migraine. Neurology 1993, 43 (Suppl. 3), S43-S47.
10. (b) Plosker, G. L.; McTavish, D. Sumatriptan: A Reappraisal of its Pharmacology and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster headache. Drugs 1994, 47, 622-641.
11. (a) Ferrari, M. D.; Saxena, P. R. Clinical and Experimental Effects of Sumatriptan in Humans. Trends Pharmacol. Sci. 1993, 14, 129-133.
12. 1F receptor. Poster presentation 52,812 at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., November 1996.
13. 1F receptor agonist. 8th Congress of the International Headache Society, Amsterdam, June 10-14, 1997.
14. 1D receptors: pharmacology and therapeutic potential. Serotonin 1996, 1, 19-29.
15. Sullivan, J. T.; Preston, K. L.; Testa, M. P.; Busch, M.; Jasinski, D. R. Psychoactivity and abuse potential of sumatriptan. Clin. Pharmacol. Ther. 1992, 52, 635-642.
16. 1 receptor agonist, sumatriptan, for the treatment of migraine. Drug Dev. Res. 1992, 26, 235-240.
17. For leading references, see: (a) MacLeod, A. M.; Street, L. J.; Reeve, A. J.; Jelley, R. A.; Sternfeld, F.; Beer, M. S.; Stanton, J. A.; Watt, A. P.; Rathbone, D.; Matassa, V. G. J. Med. Chem. 1997, 40, 3501-3503.
18. (b) Castro, J. L.; Street, L. J.; Guiblin, A. R.; Jelley, R. A.; Russell, M. G. N.; Sternfeld, F.; Beer, M. S.; Stanton, J. A.; Matassa, V. G. J. Med. Chem. 1997, 40, 3497-3500.
19. (c) Street, L. J.; Baker, R.; Davey, W. B.; Guiblin, A. R.; Jelley, R. A.; Reeve, A. J.; Routledge, H.; Sternfeld, F.; Watt, A. P.; Beer, M. S.; Middlemiss, D. N.; Noble, A. J.; Stanton, J. A.; Scholey, K.; Hargreavea, R. J.; Sohal, B.; Graham, M. I.; Matassa, V. G. J. Med. Chem. 1995, 38, 1799-1810.
20. (d) Castro, J. L.; Baker, R.; Guiblin, A. R.; Hobbs, S. C.; Jenkins, M. R.; Russell, M. G. N.; Beer, M. S.; Stanton, J. A.; Scholey, K.; Hargreaves, R. J.; Graham, M. I.; Matassa, V. G. J. Med. Chem. 1994, 37, 3023-3032.
21. (e) Glennon, R. A.; Hong, S. S.; Dukat, M.; Teitler, M.; Davis, K. J. Med. Chem. 1994, 37, 2828-2830.
22. (f) Macor, J. E.; Blank, D. H.; Fox, C. B.; Lebel, L. A.; Newman, M. E.; Post, P. J.; Ryan, K.; Schmidt, A. W.; Schulz, D. W.; Koe, B. K. J. Med. Chem. 1994, 37, 2509-2512.
23. (g) Street, L. J.; Baker, R.; Castro, J. L.; Chambers, M. S.; Guiblin, A. R.; Hobbs, S. C.; Matassa, V. G.; Reeve, A. J.; Beer, M. S.; Middlemiss, D. N.; Noble, A. J.; Stanton, J. A.; Scholey, K.; Hargreaves, R. J. J. Med. Chem. 1993, 36, 529-1538.
24. (a) Oxford, A. W.; Butina, D.; Owen, M. R. Preparation and formulation of 3-(4-piperidinyl)indole-5-ethanesulfonamides for treatment of headache. U.S. Pat. Appl. 4,997841.
25. (b) Kempsford, R. D.; Lacey, L. F.; Keene, O. N.; Thomas, M. Proc. BPS, 1993, 170P.
26. (a) Cutler, N. R.; Claghorn, J.; Sramek, J. J.; Block, G.; Panebianco, D.; Cheng, H.; Olah, T. V.; Reines, S. A. Pilot Study of MK-462 in Migraine. Cephalalgia 1996, 16, 113-116.
27. (b) Visser, W. H. Clinical Aspects of Rizatriptan. IBC's International Conference on Advances in Treatment and Therapeutic Development in Migraine, Boston, July 24-26, 1996.
28. Acton, G. SB209505: Preclinical Profile, Pharmacological Potential and Clinical Efficacy to Date. IBC's International Conference on Advances in Treatment and Therapeutic Development in Migraine, Boston, July 24-26, 1996.
29. 1D agents for the acute treatment of migraine headache. Headache 1994, 34, 307.
30. (b) Earl, N. L. The Clinical Effectiveness and Tolerability of Oral 311C90 in the Acute Treatment of Migraine. IBC's International Conference on Advances in Treatment and Therapeutic Development in Migraine, Boston, July 24-26, 1996.
31. 1D receptor binding affinity of these 5-alkyltryptamine analogues. For the tryptamine analogue, see: Glennon, R. A.; Ismaiel, A. M.; Chaurasia, C.; Titeler, M. Drug. Dev. Res. 1991, 22, 25-36. For the synthesis of 5-methyl- and 5-ethyltryptamines, see: ref 22 and Glennon, R. A.; Hong, S. S.; Bondarev, M.; Law, H.; Dukat, M.; Rakhit, S.; Power, P.; Fan, E.; Kinneau, D.; Kamboj, R.; Titeler, M.; Herrick-Davis, K.; Smith, C. J. Med. Chem. 1996, 39, 314-322.
32. 1D receptor binding affinity of these 5-alkyltryptamine analogues. For the tryptamine analogue, see: Glennon, R. A.; Ismaiel, A. M.; Chaurasia, C.; Titeler, M. Drug. Dev. Res. 1991, 22, 25-36. For the synthesis of 5-methyl- and 5-ethyltryptamines, see: ref 22 and Glennon, R. A.; Hong, S. S.; Bondarev, M.; Law, H.; Dukat, M.; Rakhit, S.; Power, P.; Fan, E.; Kinneau, D.; Kamboj, R.; Titeler, M.; Herrick-Davis, K.; Smith, C. J. Med. Chem. 1996, 39, 314-322.
33. Witte, J.; Boekelheide, V. J. Org. Chem. 1972, 37, 2849-2853.
34. Robinson, B. The Fischer Indole Synthesis; John Wiley and Sons: New York, 1982; 487-495.
35. Sasaki, T.; Minamoto, K; Itoh, H. J. Org. Chem. 1978, 43, 2320-2325.
36. Kardos, N.; Genet. J.-P. Tetrahedron: Asymmetry 1994, 5(8), 1525-1533.
37. Moyer, M. P.; Shiurba, J. F.; Rapoport, H. J. Org. Chem. 1986, 51, 5106-5110.
38. Bieg, T.; Szeja, W. Synthesis 1985, 76-76.
39. Zgombick, J. M.; Weinshank, R. L.; Macchi, M.; Schechter, L. E.; Branchek, T. A.; Hartig, P. R. Mol. Pharmacol. 1991, 40, 1036-1042.
40. Zgombick, J. M.; Borden, L. A.; Cochran, T. L.; Kucharewicz, S. A.; Weinshank, R. L.; Branchek, T. A. Mol. Pharmacol. 1993, 44, 575-582.
41. Audia, J. E.; Evrard, D. A.; Murdoch, G. R.; Droste, J. J.; Nissen, J. S.; Schenck, K. W.; Fludzinski, P.; Lucaites, V. L.; Nelson, D. L.; Cohen, M. L. J. Med. Chem. 1996, 39, 2773-2780.